Compare Hyatt Hotels Corporation (H) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Moderna, Inc. — how do they compare? Hyatt Hotels Corporation trades at $189 (market cap $17.85B), while Moderna, Inc. trades at $60.04 (market cap $23.60B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.32% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| H | MRNA | |
|---|---|---|
Market Cap | $17.85B | $23.60B |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $81.80 |
52-Week Low | $135.01 | $22.36 |
Enterprise Value | $21.69B | $19.70B |
Dividend Yield | 0.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $189.75, down 0.47% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $198. Recent earnings show mixed results, with Q2 2026 expected at $0.89 EPS. The company maintains strategic expansions, including new hotel openings and partnerships, while facing profitability challenges with a negative net income margin of -0.48% in 2025.
The stock presents a moderate buy opportunity with analyst support, but risks include declining cash flows and elevated debt. Upside hinges on execution of growth initiatives and improved earnings, while macroeconomic pressures on travel demand pose headwinds. Investors should weigh the 37.5% buy rating against fundamental weaknesses.
Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.
The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
